To the content
2 . 2022

Discontinuation of antiplatelet and anticoagulant therapy before surgery


The article reviews principles of antithrombotic discontinuation before surgery. Low-dose aspirin doesn’t need to be withdrawn prior to surgery. Clopidogrel usually need to be discontinued  3–7 days before invasive procedure. DAPT usually discontinued prior medium or high risk procedures. Vitamin K antagonists need to be discontinued 3–5 days before surgery (warfarin – 5–7 days before procedure). Per oral anticoagulants are discontinued 48 hours before high risk surgery (e.g. aortic procedures). We need to include these recommendations in residency programs. 

Keywords:antithrombotic therapy; surgical interventions; рer oral anticoagulants; сlopidogrel; acetylsalicylic acid

Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
For citation: Kharazov A.F., Basirova N.M., Markov A.A. Discontinuation of antiplatelet and anticoagulant therapy before surgery. Clinical and Experimental Surgery. Petrovsky Journal. 2022; 10 (2): 112–9. DOI:  (in Russian)


1.      Lutsey P.L. Direct oral anticoagulants and warfarin for venous thromboembolism treatment: trends from 2012 to 2017. Res Pract Thromb Haemost. 2019; 3 (4): 668–73. DOI:  Epub 2019 Jun 9.

2.      X-ray endovascular diagnosis and treatment of diseases of the heart and blood vessels in the Russian Federation – 2020. Endovaskulyarnaya khirurgiya [Endovascular surgery]. 2021; 8 (spec issue). DOI:  (in Russian)

3.      Perioperative management of patients receiving long-term antithrombotic therapy. Clinical recommendations of the Federation of anesthesiologists and resuscitators. Moscow, 2019. (in Russian)

4.      Chopra V., Wesorick D.H., Sussman J.B., Greene T.,  Rogers M., Froehlich J.B., et al. Effect of peri-operative statins on death, myocardial infarction, atrial fibrillation, and length of stay: a systematic review and meta-analysis. Arch Surg. 2012; 147:  181–9.

5.      Burger W., Chemnitius J.M., Kneissl G.D., Rucker G. Low-dose aspirin for secondary cardiovascular prevention: cardiovascular risks after its peri-operative withdrawal vs bleeding risks with its continuation: review and meta-analysis. J Intern Med. 2005; 257: 399–414.

6.      Stone D.H., Goodney P.P., Schanzer A., Nolan B.W.,  Adams J.E., Powell R.J.,  et al.; Vascular Study Group of New England. Clopidogrel is not associated with major bleeding complications during peripheral arterial surgery. J Vasc Surg. 2011; 54 (3): 779–84. DOI:  

7.      Jones D.W., Schermerhorn M.L., Brooke B.S., Conrad M.F., Goodney P.P., Wyers M.C., et al.; Stone and for the Vascular Quality Initiative. Perioperative clopidogrel is associated with increased bleeding and blood transfusion at the time of lower extremity bypass. J Vasc Surg. 2017; 65 (6): 1719–28.e1. DOI:  

8.      Saadeh C., Sfeir J. Discontinuation of preoperative clopidogrel is unnecessary in peripheral arterial surgery. J Vasc Surg. 2013; 58 (6): 1586–92. DOI:  Epub 2013 Jul 24.

9.      Feres F.; OPTIMIZE Trial Investigators, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013; 310 (23): 2510–22. DOI:  

10.   Vivas D., et al. Perioperative and periprocedural management of antithrombotic therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT and AEU. Rev Esp Cardiol (Engl Ed). 2018; 71 (7): 553–64. DOI:  Epub 2018 Jun 8.

11.   Vahanian A., Alfieri O., Andreotti F., Antunes M.J., Baron-Esquivias G., Baumgartner H., et al. Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2012; 33: 2451–96.

12.   Pengo V., Cucchini U., Denas G., Erba N., Guazzaloca G.,  La Rosa L., et al. Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation. 2009; 119: 2920–7.

13.   De Caterina R., et al. Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. Heart. 2014; 100 (20): 1625–35. DOI:  Epub 2014 Aug 8.

14.   Lopes RD, et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019 Apr 18; 380 (16) :1509-1524. doi: 10.1056/NEJMoa1817083. Epub 2019 Mar 17.

15.   Novikova N.A., Shilova A.S. Features of prescribing triple antithrombotic therapy using rivaroxaban in patients with atrial fibrillation who underwent coronary artery stenting. Aterotromboz [Atherothrombosis]. 2017; (1): 114–21. DOI:  (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

Sergey L. Dzemeshkevich
MD, Professor (Moscow, Russia)

Journals of «GEOTAR-Media»